Trying to predict where the market for biotech investment is heading is risky but for experts like Baker McKenzie’s Roel Meers, understanding where the market is moving is where he eats.
Interleukins — a group of signaling proteins that help immune cells communicate — have long been recognized as powerful tools in modulating immune responses. Over the years, companies have explored interleukin as treatments for cancer, autoimmune conditions, and inflammatory diseases. But while some interleukin-based drugs have reached the market, many early attempts were held back […]
Generative artificial intelligence’s biggest impacts on biotech are still to come. Learn more in our talk with Cradle Therapeutics’s co-founder, Elise de Reus.